MA55809A - Formulation d'anticorps anti-il-6 - Google Patents

Formulation d'anticorps anti-il-6

Info

Publication number
MA55809A
MA55809A MA055809A MA55809A MA55809A MA 55809 A MA55809 A MA 55809A MA 055809 A MA055809 A MA 055809A MA 55809 A MA55809 A MA 55809A MA 55809 A MA55809 A MA 55809A
Authority
MA
Morocco
Prior art keywords
antibody formulation
antibody
formulation
Prior art date
Application number
MA055809A
Other languages
English (en)
Other versions
MA55809B1 (fr
Inventor
Madhav N Devalaraja
Mark Melville
Zahra Shahrokh
Gaozhong Zhu
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA55809A publication Critical patent/MA55809A/fr
Publication of MA55809B1 publication Critical patent/MA55809B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MA55809A 2019-05-01 2020-04-30 Formulations d'anticorps anti-il-6 MA55809B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962841662P 2019-05-01 2019-05-01
EP19181345 2019-06-19
EP20728590.9A EP3962942B1 (fr) 2019-05-01 2020-04-30 Formulations d'anticorps anti-il-6
PCT/US2020/030865 WO2020223565A1 (fr) 2019-05-01 2020-04-30 Formulation d'anticorps anti-il-6

Publications (2)

Publication Number Publication Date
MA55809A true MA55809A (fr) 2022-03-09
MA55809B1 MA55809B1 (fr) 2025-12-31

Family

ID=70857238

Family Applications (1)

Application Number Title Priority Date Filing Date
MA55809A MA55809B1 (fr) 2019-05-01 2020-04-30 Formulations d'anticorps anti-il-6

Country Status (8)

Country Link
EP (3) EP4591885A3 (fr)
JP (3) JP7701273B2 (fr)
ES (1) ES3055418T3 (fr)
HR (1) HRP20251529T1 (fr)
MA (1) MA55809B1 (fr)
PL (1) PL3962942T3 (fr)
RS (1) RS67540B1 (fr)
WO (1) WO2020223565A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6808194A (en) 1993-05-31 1994-12-20 Chugai Seiyaku Kabushiki Kaisha Reconstructed human antibody against human interleukin-6
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
ES2436206T3 (es) 2001-11-14 2013-12-27 Janssen Biotech, Inc. Anticuerpos anti il-6, composiciones, métodos y usos
CA2496523A1 (fr) 2002-08-30 2004-03-11 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anticorps d'interleukine-6 antihumaine de type humain et fragment de l'anticorps
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
DK2444424T3 (en) 2005-05-20 2018-12-03 Ablynx Nv IMPROVED NANOL BODIES (TM) FOR TREATING AGGREGATED MEDICINAL DISORDERS
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
JP2012516158A (ja) 2009-01-29 2012-07-19 メディミューン，エルエルシー 延長したインビボ半減期を有するヒト抗ｉｌ−６抗体ならびに腫瘍学、自己免疫疾患、および炎症性疾患の治療におけるそれらの使用
EP2399604A1 (fr) * 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Nouvelle formulation d'anticorps
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
CN106421782A (zh) 2012-10-25 2017-02-22 米迪缪尼有限公司 稳定的低粘度抗体配制品
KR102709681B1 (ko) 2015-07-31 2024-09-26 메디뮨 리미티드 헵시딘 매개 장애의 치료 방법
CA3012350A1 (fr) 2016-02-23 2017-08-31 Sesen Bio, Inc. Formulations d'antagonistes d'il-6 et leurs utilisations
WO2018144773A1 (fr) 2017-02-01 2018-08-09 Yale University Traitement de la résistance aux diurétiques
JP7395479B2 (ja) 2018-01-05 2023-12-11 ノヴォ ノルディスク アー／エス 免疫抑制なしにｉｌ－６媒介性炎症を処置する方法

Also Published As

Publication number Publication date
JP7701273B2 (ja) 2025-07-01
JP2025166156A (ja) 2025-11-05
ES3055418T3 (en) 2026-02-11
MA55809B1 (fr) 2025-12-31
EP4591885A3 (fr) 2025-11-19
JP7755766B2 (ja) 2025-10-16
RS67540B1 (sr) 2026-01-30
EP4591885A2 (fr) 2025-07-30
PL3962942T3 (pl) 2026-02-16
WO2020223565A1 (fr) 2020-11-05
EP3962942C0 (fr) 2025-10-22
EP4631523A3 (fr) 2025-12-31
EP3962942B1 (fr) 2025-10-22
JP2022531331A (ja) 2022-07-06
HRP20251529T1 (hr) 2026-01-16
EP4631523A2 (fr) 2025-10-15
JP2025114623A (ja) 2025-08-05
EP3962942A1 (fr) 2022-03-09

Similar Documents

Publication Publication Date Title
MA49043A (fr) Formulation stable d'anticorps
MA54052A (fr) Formulation d'anticorps
EP3618871A4 (fr) Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
MA56006A (fr) Formulations sous-cutanées d'anticorps her2
MA51747A (fr) Formulation d'anticorps pharmaceutique à ph faible
EP3765522A4 (fr) Anticorps anti-claudine 18.2
MA51903A (fr) Formulations d'anticorps b7-h4
MA54139A (fr) Formulation d'anticorps
EP3823978A4 (fr) Compositions d'anticorps anti-fcrn
EP3927729A4 (fr) Formulation d'anticorps thérapeutique
EP3807318A4 (fr) Constructions d'anticorps multi-spécifiques
MA55600A (fr) Anticorps anti-ige
EP3496753A4 (fr) Formulation d'anticorps anti-pd-1
EP3849612A4 (fr) Variants d'anticorps anti-vih 10-1074
MA52152A (fr) Anticorps
EP4023292A4 (fr) Formulation d'injection
EP3995582A4 (fr) Anticorps anti-epha4
EP3735987A4 (fr) Conjugué d'anticorps à base d'amanitine
EP4188544A4 (fr) Formulations d'anticorps anti-connexine
MA53466A (fr) Formulation stable d'anticorps anti-osmr
EP3867272A4 (fr) Utilisation d'anticorps anti-fam19a5
EP3986415A4 (fr) Formulations d'ibogaïne
EP3947466A4 (fr) Anticorps anti-hla-dq2.5
IL286024A (en) Stabilized formulations containing anti-il-33 antibodies
IL283886A (en) Antibody formulations